Outsourcing Pharma

APRIL 23, 2024

At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US.

76

76

Fierce Pharma

MARCH 10, 2023

Gilead Sciences, after long battle against HIV drug fraudsters, scores $175.2M in judgements zbecker Fri, 03/10/2023 - 11:55

90

90

STAT

MAY 23, 2023

Seattle biotech Achieve Life Sciences on Tuesday announced an experimental drug meant to help people quit smoking did exactly that in a clinical trial, paving the way for the company to seek approval for a product that would face stiff competition.

100

100

pharmaphorum

JANUARY 20, 2022

Patients rely on drugs, and sometimes surgery, for periods of relief from symptoms. The post UK green lights Gilead Sciences, Galapagos ulcerative colitis drug appeared first on. The additional indication for UC was granted based on results from the developers’ phase IIb/III SELECTION programme.

98

98

Drug Store News

AUGUST 15, 2023

Thomas Swalla, CEO of Dotmatics, takes a look at how the power of data science can help aid in R&D innovations.

95

95

STAT

APRIL 25, 2024

University of Washington professor David Baker has made a name for himself by borrowing computer science concepts like machine learning and artificial intelligence to solve problems in biology. Now Baker is pushing forward in a different area of drug discovery research.

Compounding 133

Compounding 133

Fierce Pharma

APRIL 1, 2024

Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway with an asthma resc | Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar (..)

117

117

Fierce Pharma

APRIL 26, 2024

After a negative phase 3 readout, Gilead Sciences is taking a $2.4 After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on the antibody-drug conjugate Trodelvy. billion impairment charge on Trodelvy, which serves as the cornerstone of the company’s solid tumor ambition.

107

107

STAT

MARCH 14, 2024

What happens when an approved drug doesn’t work? Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. Why don’t patients want gene therapy? And is MASH still a big deal? Read the rest…

123

123

STAT

APRIL 10, 2024

Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 The drug will enter Phase 3 clinical development in the second half of the year. billion, the companies announced Wednesday. It is the largest acquisition in Vertex’s history.

Immunization 144

Immunization 144

Pharma Times

APRIL 17, 2024

Both companies will facilitate career progression while advancing the life sciences industry

44

44

Fierce Pharma

NOVEMBER 30, 2023

The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal. | The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1

130

130

STAT

APRIL 22, 2024

Want to stay on top of the science and politics driving biotech today?  Up today: an exclusive look at the scientific mix-up behind the approval of preterm birth drug Makena.   Sign up  to get our biotech newsletter in your inbox. Hope you had a delightful weekend. Continue to STAT+ to read the full story…

FDA 104

FDA 104

STAT

APRIL 15, 2024

Nelsen, managing director of ARCH Venture, had made a name and fortune off crazy ideas, but generally it was the science that sounded crazy: engineering cells to cure cancer, finding drugs to slow aging. “This is a crazy idea,” Sato said. This new idea was financially crazy.

144

144

European Pharmaceutical Review

JANUARY 11, 2024

Quotient Sciences leverage more than 30 years of drug development expertise to support small molecule and synthetic peptide drug programmes, in both simple drug programmes as well as complex cases where specialised formulation expertise and technologies are required.

103

103

STAT

OCTOBER 17, 2023

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

FDA 142

FDA 142

pharmaphorum

FEBRUARY 16, 2024

Gilead Sciences has paused enrolment in clinical trials of its CD47 drug magrolimab in solid tumours, a week after dropping it for blood cancers.

121

121

STAT

MARCH 16, 2024

A round this time three years ago, while most of us   navigated pandemic life, real estate developers across Greater Boston looked to life-science laboratories, and saw dollar signs.   Life-science companies, and the lab buildings that house them, looked like a sure bet for investors.

126

126

STAT

APRIL 1, 2024

Want to stay on top of the science and politics driving biotech today?  health agency make a controversial call about an ALS drug made by Biogen, and more.   Sign up  to get our biotech newsletter in your inbox. We see a U.K.

FDA 113

FDA 113

pharmaphorum

FEBRUARY 5, 2024

Data science in healthcare is transforming the industry, from drug discovery to patient care. Learn about the role of data, artificial intelligence (AI), and the impact of initiatives like the NHS Datastore in revolutionising healthcare outcomes.

Patient Care 124

Patient Care 124

STAT

FEBRUARY 15, 2024

The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. Read the rest…

102

102

STAT

MARCH 15, 2024

Want to stay on top of the science and politics driving biotech today?  Today, we see the first approval of a drug to treat MASH, a Gilead medication shows huge promise in Ebola, and more.   Sign up  to get our biotech newsletter in your inbox. Read the rest…

FDA 107

FDA 107

Outsourcing Pharma

APRIL 11, 2024

In a groundbreaking revelation, a study conducted by RCSI University of Medicine and Health Sciences and Childrenâs Health Ireland has confirmed the safety and efficacy of a Cystic Fibrosis drug in newborns as young as four weeks old.

93

93

STAT

JANUARY 3, 2024

Food and Drug Administration approved nearly 50% more novel drugs in 2023 than in 2022, putting it back on pace with historical levels, an improvement analysts and investors said could lead to increased investment in biotech firms , Reuters writes. The agency also approved five gene therapies in addition to the 55 novel drugs.

FDA 110

FDA 110

pharmaphorum

FEBRUARY 12, 2024

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for primary biliary cholangitis (PBC) for $4.3bn

108

108

pharmaphorum

MARCH 12, 2024

In the latest episode of the pharmaphorum podcast, host Nicole Raleigh speaks (virtually) with Nathan Clark, founder and CEO of Ganymede, a modern data platform and Cloud infrastructure for science, to discuss the evolving role of the Cloud in biopharma and some rather revolutionary tools in AI drug discovery.

113

113

Fierce Pharma

FEBRUARY 29, 2024

Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry.

104

104

PharmExec

JANUARY 8, 2024

Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.

126

126

Drug Topics

OCTOBER 11, 2022

Drug Topics® is joined by Dr. Alex Capano, Chief Science Officer at Ananda professional to discuss what CBD is used for in dermatology.

200

200

STAT

APRIL 3, 2024

Want to stay on top of the science and politics driving biotech today?  Today we talk about how biopharma plans to harness AI for clinical trial design, why two experts think Medicare ought to cover the costly GLP-1 drugs, and what news from Roivant means for its business strategy. Read the rest…

103

103

Drug Topics

OCTOBER 27, 2022

Drug Topics® is joined by Dr. Alex Capano, Chief Science Officer at Ananda professional to discuss what CBD is used for mental health, where research should go next, and how to ensure that patients are getting effective CBD products.

201

201

pharmaphorum

FEBRUARY 8, 2024

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.

116

116

pharmaphorum

FEBRUARY 29, 2024

Explore the impact of the Inflation Reduction Act (IRA) on drug prices and negotiations within the life sciences industry, as it stands on the threshold of change. Gain insights into the potential outcomes and implications of this legislation.

106

106

STAT

APRIL 17, 2024

Want to stay on top of the science and politics driving biotech today?  Beyond that, we see up close how Amylyx’s ALS drug — which it is pulling from the market — really didn’t differ much from placebo, and see more market and investment potential for psychedelics.

101

101

STAT

MARCH 14, 2024

Want to stay on top of the science and politics driving biotech today?  Damian here with a reminder that my colleague Ed Silverman is hosting a discussion today about the long-awaited arrival of Humira biosimilars and all they portend for drug costs, insurance coverage, and pharma revenues. Hello, everyone.

Insurance Coverage 113

Insurance Coverage Insurance 113

STAT

APRIL 10, 2024

Want to stay on top of the science and politics driving biotech today?  Also, advocates press the federal government to encourage manufacturing for the prostate cancer drug Xtandi. Also, advocates press the federal government to encourage manufacturing for the prostate cancer drug Xtandi. Read the rest…

Insurance 94

Insurance 94

STAT

FEBRUARY 6, 2024

Its decision, the company explained, is not a response to new data about the drug’s safety or efficacy, but instead “a reprioritization of resources.” ” Simply put, it wasn’t about science or medicine. It was about money. I don’t condone the company’s behavior, but I do understand it.

FDA 145

FDA 145